# FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-cosibelimab-ipdl-for-metastatic-or-locally-advanced-cutaneous-squam-cebe393662e72642
Kind: launch · Impact: medium

## In brief

- On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) from Checkpoint Therapeutics.
- The drug is a PD-L1 blocking antibody.
- It is approved for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.

## Why it matters

This adds a PD-L1 blocking antibody option for adults with advanced cutaneous squamous cell carcinoma, a skin cancer that can spread beyond its original site.

## Timeline

- 2024-12-13: FDA approves cosibelimab-ipdl (Unloxcyt) for metastatic or locally advanced cutaneous squamous cell carcinoma

## Coverage

- [FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma](http://www.fda.gov/drugs/cancer-approvals/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma) — What's New: Drugs RSS Feed, 2026-11-07

Tags: fda, oncology, immunotherapy, cutaneous-squamous-cell-carcinoma, pd-l1, drug-approval

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science